Compare AREC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AREC | AURA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.4M | 396.8M |
| IPO Year | 2019 | 2021 |
| Metric | AREC | AURA |
|---|---|---|
| Price | $2.87 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.67 | ★ $20.33 |
| AVG Volume (30 Days) | ★ 7.0M | 211.6K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,026.00 | N/A |
| Revenue This Year | $178.94 | N/A |
| Revenue Next Year | $903.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $4.35 |
| 52 Week High | $7.11 | $9.53 |
| Indicator | AREC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 53.55 |
| Support Level | $2.56 | $5.31 |
| Resistance Level | $2.94 | $6.62 |
| Average True Range (ATR) | 0.38 | 0.33 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 25.17 | 54.17 |
American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.